Abnormalities of the resistance vasculature in hypertension: Correction by vasodilator therapy

Pharmacological Reports

Volumn 57, Issue SUPPL., 2005, Pages 144-150

  Mulvany, Michael J ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

ACE inhibitor; Antihypertensive therapy; Beta blocker; Small artery; Structure; Tissue transglutaminase

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD FLOW; BLOOD VESSEL DIAMETER; BLOOD VESSEL WALL; CELL INTERACTION; ESSENTIAL HYPERTENSION; EXTRACELLULAR MATRIX; HUMAN; HYPEREMIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ORGAN CULTURE; RESISTANCE BLOOD VESSEL; REVIEW; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

EID: 33645676559     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ: Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation-contraction coupling in isolated resistance vessels from essential hypertensives. Circ Res, 1987, 61, 181-186.
2. Bakker EN, Buus CL, Spaan JA, Perree J, Ganga A, Rolf TM, Sorop O et al.: Small artery remodelling depends on tissue-type transglutaminase. Circ Res, 2005, 96, 119-126.
3. Bakker EN, Buus CL, VanBavel E, Mulvany MJ: Activation of resistance arteries with endothelin-1: from vaso-constriction to functional adaptation and remodeling. J Vasc Res, 2004, 41, 174-182.
4. Bakker EN, van Der Meulen ET, Spaan JA, VanBavel E: Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling. Am J Physiol, 2001, 278, H1233-H1240.
5. Bakker EN, van Der Meulen ET, van den Berg BM, Everts V, Spaan JA, VanBavel E: Inward remodeling follows chronic vasoconstriction in isolated resistance arteries. J Vasc Res, 2002, 39, 12-20.
6. Buus CL, Pourageaud F, Fazzi GE, Janssen G, Mulvany MJ, De Mey JGR: Smooth muscle changes during flow-related remodeling of rat mesenteric resistance arteries. Circ Res, 2001, 89, 180-186.
7. Buus NH, Bottcher M, Jorgensen CG, Christensen KL, Thygesen K, Nielsen TT, Mulvany MJ: Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension, 2004, 44, 465-470.
8. Christensen KL, Mulvany MJ: Location of resistance arteries. J Vasc Res, 2001, 38, 1-12.
9. Christensen KL, Mulvany MJ: Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens, 2001, 19, 1001-1006.
10. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J et al.: Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet, 1990, 335, 827-838.
11. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995-1003.
12. Folkow B: Structural, myogenic, humoral and nervous factors controlling peripheral resistance. In: Hypotensive Drugs. Ed. Harington M, Pergamon, London, 1956, 63-174.
13. Guyton AC: Renal function curve - a key to understanding the pathogenesis of hypertension. Hypertension, 1987, 10, 1-6.
14. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ: Small artery structure in hypertension: dual processes of remodelling and growth. Hypertension, 1993, 21, 391-397.
15. Julius S: The blood pressure seeking properties of the central nervous system. J Hypertens, 1988, 6, 177-185.
16. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc, 2002, 288, 2981-2997.
17. Mulvany MJ: Pharmacological treatment of resistance vessel remodelling in hypertension. In: Proceedings of the Indian Pharmacological Society Meeting, 2003. (in press).
18. Mulvany MJ: Remodelling of resistance vessels in essential hypertension. In: Hypertension. Ed. Oparill S, Weber HA, Saunders, Philadelphia, 2000, 125-134.
19. Mulvany MJ: Resistance vessel growth and remodelling: cause or consequence in cardiovascular disease. J Hum Hypertens, 1995, 9, 479-485.
20. Mulvany MJ: Small artery remodeling in hypertension. Curr Hypertens Rep, 2002, 4, 49-55.
21. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD: Vascular remodelling (Letter to Editor). Hypertension, 1996, 28, 505-506.
22. Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res, 1977, 41, 19-26.
23. Mulvany MJ, Hansen PK, Aalkjaer C: Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res, 1978, 43, 854-864.
24. Park JB, Charbonneau F, Schiffrin EL: Correlation of endothelial function in large and small arteries in human essential hypertension. J Hypertens, 2001, 19, 415-420.
25. Schiffrin EL, Deng LY, Larochelle P: Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension, 1994, 23, 83-91.
26. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation, 2000, 101, 1653-1659.
27. Strauer BE, Schwartzkopff B: Left ventricular hypertrophy and coronary microcirculation in hypertensive heart disease. Blood Press Suppl, 1997, 2, 6-12.
28. Su EJ, Lombardi DM, Siegal J, Schwartz SM: Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension, 1998, 31, 1331-1337.
29. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension, 1995, 25, 474-481.
30. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New Engl J Med, 2003, 348, 583-592.